CN115867540A - 硝羟喹啉衍生物及其制备方法和用途 - Google Patents

硝羟喹啉衍生物及其制备方法和用途 Download PDF

Info

Publication number
CN115867540A
CN115867540A CN202180049565.7A CN202180049565A CN115867540A CN 115867540 A CN115867540 A CN 115867540A CN 202180049565 A CN202180049565 A CN 202180049565A CN 115867540 A CN115867540 A CN 115867540A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
halogen
heterocyclyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049565.7A
Other languages
English (en)
Inventor
吴亮
邓一军
肖璐
潘柯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yahong Pharmaceutical Technology Co ltd
Jiangsu Yahong Pharmaceutical Technology Co ltd
Original Assignee
Shanghai Yahong Pharmaceutical Technology Co ltd
Jiangsu Yahong Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yahong Pharmaceutical Technology Co ltd, Jiangsu Yahong Pharmaceutical Technology Co ltd filed Critical Shanghai Yahong Pharmaceutical Technology Co ltd
Publication of CN115867540A publication Critical patent/CN115867540A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了硝羟喹啉衍生物及其制备方法和用途。具体地，本发明公开了通式(I)所示的化合物、其制备方法、含有其的药物组合物，以及其在治疗感染性疾病或癌症中的用途。本发明的化合物具有优异的抗肿瘤活性和抑菌活性，可以被开发为***、感染性疾病的药物。通式(I)中各基团的定义与说明书中相同。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202180049565.7A 2020-08-03 2021-07-30 硝羟喹啉衍生物及其制备方法和用途 Pending CN115867540A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010767532.3A CN111960998A (zh) 2020-08-03 2020-08-03 硝羟喹啉衍生物及其制备方法和用途
CN2020107675323 2020-08-03
PCT/CN2021/109592 WO2022028321A1 (zh) 2020-08-03 2021-07-30 硝羟喹啉衍生物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN115867540A true CN115867540A (zh) 2023-03-28

Family

ID=73363420

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010767532.3A Pending CN111960998A (zh) 2020-08-03 2020-08-03 硝羟喹啉衍生物及其制备方法和用途
CN202180049565.7A Pending CN115867540A (zh) 2020-08-03 2021-07-30 硝羟喹啉衍生物及其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010767532.3A Pending CN111960998A (zh) 2020-08-03 2020-08-03 硝羟喹啉衍生物及其制备方法和用途

Country Status (5)

Country Link
US (1) US20230295094A1 (zh)
EP (1) EP4194441A1 (zh)
CN (2) CN111960998A (zh)
TW (1) TW202214570A (zh)
WO (1) WO2022028321A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111960998A (zh) * 2020-08-03 2020-11-20 江苏亚虹医药科技有限公司 硝羟喹啉衍生物及其制备方法和用途
CA3218645A1 (en) * 2021-05-31 2022-12-08 Yijun Deng 7-nitro-8-hydroxyquinoline derivative, preparation method therefor and medical use thereof
CN113527370B (zh) * 2021-08-26 2022-07-15 玉林师范学院 一种靶向于肺癌顺铂耐药细胞的喹啉铱配合物及其合成方法和应用
CN113683644B (zh) * 2021-08-26 2022-05-20 玉林师范学院 一种治疗顺铂耐药癌细胞的双喹啉铱配合物及其制备方法和应用
CN117186002A (zh) * 2022-05-31 2023-12-08 江苏亚虹医药科技股份有限公司 7-氰基-8-羟基喹啉衍生物、其制备方法及其医药用途
CN117224542A (zh) * 2022-06-07 2023-12-15 江苏亚虹医药科技股份有限公司 硝羟喹啉类化合物增强抗菌剂作用的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239149A (zh) * 2008-10-06 2011-11-09 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
US20120071505A1 (en) * 2009-08-17 2012-03-22 High Point Pharmaceuticals, Llc Substituted pyridine derivatives, pharmaceutical compositions, and methods of use to treat oxidative stress
WO2016154051A1 (en) * 2015-03-20 2016-09-29 University Of Florida Research Foundation, Inc. Combination therapy for treating infections diseases
CN109111426A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
CN111960998A (zh) * 2020-08-03 2020-11-20 江苏亚虹医药科技有限公司 硝羟喹啉衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014906A2 (en) * 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
EP2970128B1 (en) * 2013-03-15 2019-12-04 Asieris Pharmaceutical Technologies Co., Ltd. Base addition salts of nitroxoline and uses thereof
CN103319404A (zh) * 2013-05-30 2013-09-25 苏州康润医药有限公司 一种硝羟喹啉衍生物及其作为血管生成抑制剂的应用
BR112018069670A2 (pt) * 2016-03-31 2019-01-29 Asieris Pharmaceutical Tech Co Ltd usos combinatoriais de nitroxolina e seus análogos com quimioterapias e imunoterapias no tratamento de cânceres
HUP1600234A2 (en) * 2016-04-05 2017-12-28 Mta Termeszettudomanyi Kutatokoezpont Mdr-reversing 8-hydroxy-quinoline derivatives
CN109467533A (zh) * 2018-12-14 2019-03-15 兰州大学 一种8-羟基喹啉类化合物及其制备方法和在防治农业病害中的用途
CN110305122B (zh) * 2019-06-26 2022-10-25 华东师范大学 一种吡啶环C4位磺酰基、磷氧基官能团化的Pybox配体及其合成方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239149A (zh) * 2008-10-06 2011-11-09 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
US20120071505A1 (en) * 2009-08-17 2012-03-22 High Point Pharmaceuticals, Llc Substituted pyridine derivatives, pharmaceutical compositions, and methods of use to treat oxidative stress
WO2016154051A1 (en) * 2015-03-20 2016-09-29 University Of Florida Research Foundation, Inc. Combination therapy for treating infections diseases
CN109111426A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
CN111960998A (zh) * 2020-08-03 2020-11-20 江苏亚虹医药科技有限公司 硝羟喹啉衍生物及其制备方法和用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"REGISTRY数据库新颖性化合物", REGISTRY, pages 1 - 60 *
HERMAN GERSHON: "Antifungal activity of 7- and 5, 7-substituted 8-quinolinols", JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 9, pages 987 *
NAJI M. ALI: "Palladium-catalyzed cross-coupling reactions of arylboronic acids with π-deficient heteroaryl chlorides", TETRAHEDRON, vol. 48, no. 37, pages 8117 - 8126, XP028087772, DOI: 10.1016/S0040-4020(01)80481-6 *
OLGA V. DYABLO: "Synthesis of 6-methoxy-N2, N2, N4, N4, N5, N5-hexamethylquinoline-2, 4, 5-triamine - a new representative of quinoline proton sponges", CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 51, no. 3, pages 25 *
YOSHIKI HAMADA: "Quinoline derivatives. XII", YAKUGAKU ZASSHI, vol. 86, no. 3, pages 2236 *

Also Published As

Publication number Publication date
US20230295094A1 (en) 2023-09-21
EP4194441A1 (en) 2023-06-14
WO2022028321A1 (zh) 2022-02-10
TW202214570A (zh) 2022-04-16
CN111960998A (zh) 2020-11-20

Similar Documents

Publication Publication Date Title
CN115867540A (zh) 硝羟喹啉衍生物及其制备方法和用途
RU2727198C2 (ru) Производное бензофурана, способ его получения и его применение в медицине
WO2021129824A1 (zh) 新型K-Ras G12C抑制剂
CN114630832A (zh) 一种嘧啶并环衍生物及其在医药上的应用
EP3845527A1 (en) Multi-substituted pyridone derivatives and medical use thereof
KR20050009706A (ko) 안트라닐산 유도체 수화물의 제조 방법
CN110041253B (zh) 吡啶类n-氧化衍生物及其制备方法和应用
CN113330009A (zh) 氮杂环化合物、其制备方法及用途
CN113748110A (zh) 取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途
WO2022247816A1 (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN115038707A (zh) 氮杂卓类稠环化合物及其医药用途
CN110520416A (zh) 多取代吡啶酮类衍生物、其制备方法及其医药用途
KR20230118891A (ko) 신규한 캄프토테신 유도체, 이를 포함하는 조성물 및이의 용도
CN111205309B (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
CN110407854B (zh) 新的四环化合物
CN114394965B (zh) ***并吡啶类化合物及其制备方法与用途
TW202325300A (zh) 稠合醯亞胺類衍生物及其應用
KR20230107271A (ko) 이환식 유도체를 포함하는 억제제 유리염기의 결정형, 이의 제조방법 및 용도
CN115073426A (zh) 嘧啶杂环化合物及其制备方法和应用
CN113880833A (zh) 联苯多环类衍生物抑制剂、其制备方法和应用
EP2303880A2 (fr) Nouveaux derives tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN116262759B (zh) 嘧啶三环类化合物及其制备方法和医药用途
CN106349180B (zh) 4,5-二苯基异噁唑衍生物及其制备方法和应用
CN112996784B (zh) 吲哚衍生物及其在医药上的应用
CN116023396A (zh) 含氮螺环类化合物及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination